MY PICK IS ELN

[kingofthehill]

I like it from the SEC .....

http://www.sec.gov/Archives/edgar/data/737572/000095016205000820/elan6k-081605.txt

EXHIBIT LIST

Exhibit Description
------- -----------

99.1 Amendment to Employment Agreement, dated as of December 3, 2004, by
and among Elan Pharmaceuticals, Inc. and Elan Corporation, plc and G.
Kelly Martin, entered into on August 11, 2005. Mr. Martin is the
president and chief executive officer and a director of Elan
Corporation, plc. The amendment modifies the benefits to be received
by Mr. Martin in the event of an involuntary termination, extends
severance payments to three years (from two) in the event of an
involuntary termination following a change in control, modifies the
indemnification provisions of the employment agreement and adds an
attorneys' fees provision.



<PAGE>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.


ELAN CORPORATION, plc


By: /s/ William F. Daniel
--------------------------
William F. Daniel
EVP, Company Secretary

Date: August 16, 2005
</TEXT>
</DOCUMENT>

[Websman]

Possible takeover???

[Websman]

Oops....I double posted

[Websman]

Tysabri go-ahead 'likely by year-end'



ELAN Corp could receive regulatory approval for its Tysabri drug treatment for MS from the Food and Drugs Administration in the US before the end of 2005. If approved, this would allow the drug treatment back on pharmacy shelves in the US by June 2006, according to Davy Stockbrokers.

This follows the announcement on August 9 that no new cases of the fatal brain condition PML had been identified.

"The first segment of the safety evaluation on Multiple Sclerosis (MS) patients has been completed and no new cases of PML were identified. Crohn's/RA patient evaluations are on track to complete in September," Davy healthcare analyst Jack Gorman notes.

"Regulatory submissions should follow shortly thereafter, which accords with our view that a possible regulatory decision on Tysabri could be made around the end of 2005," he predicts.

Elan will be making regulatory submissions simultaneously to both the FDA in the US and the EMEA (European Medical Evaluation Authority) but the expectation among analysts is that the FDA will move fastest to approve or reject Tysabri.

Mr Gorman says Tysabri was a new molecular entity given a priority review by the FDA. This level of innovation remains relatively rare, he argues.

The launch and subsequent suspension of Tysabri has had two impacts on the MS market in the US, according to Mr Gorman.

"Firstly, Tysabri's launch raised awareness and penetration levels across the patient population, leading to a rise in underlying prescription volumes. Secondly, it raised the bar on pricing levels so revenue growth is accelerating," Mr Gorman says.

Elan remains a product-specific story notwithstanding a rising biotech sector. Davy's sum of the parts valuation for a successful launch of Tysabri implies a share price target of just over $13 a share based on peak revenues of $1.6bn.

Elan surged almost 40pc in Dublin at one stage on August 9 after it said that a safety evaluation of Tysabri had resulted in no new confirmed cases of PML.

Elan and its marketing partner for Tysabri, Biogen, said earlier this month that about 2,000 patients who took the suspended MS-fighting drug Tysabri in clinical trials have been screened for PML, but none showed signs of contracting the condition.

Jim Aughney

[Websman]

Delray neurologist to test Alzheimer's vaccine

By Stephanie Horvath

Palm Beach Post Staff Writer

Monday, August 22, 2005

A Delray Beach neurologist is one of five doctors in the country testing a new Alzheimer's vaccine in a clinical trial.

The vaccine, made by Elan Pharmaceuticals in Dublin, Ireland, should prompt the body to produce antibodies that will attack plaque that forms in the brain of Alzheimer's patients. Dr. Mark Brody, a principal investigator, said no one is certain that the plaque is the primary cause of the memory loss and mental degeneration, but it forms where memory is stored and processed.




Starting in September, Brody and his staff at Brain Matters Research will inject the vaccine into 12 patients with mild to moderate Alzheimer's in the first phase of the clinical trial. New drugs go through three phases of trials before makers seek Food and Drug Administration approval.

Brody said the trial will last two years, during which he'll evaluate patients with medical scans and exams as well as tests that assess memory, processing speed and judgment.

"Eventually, if we show a treatment is effective in people who have the disease, eventually we will start to treat people with pre-Alzheimer's," Brody said.

People who wish to participate in the trial can contact Brody at (561) 374-8461

[kingofthehill]

I really like where we are right now, things will be moving quickly

[Websman]

Here's a post from the Yahoo board, that gave me a good laugh...



NEWS: Elan Chief Defies FDA

In a move Wall Street analysts could never have anticipated, Elan CEO Kelly Martin
revealed today just how far he was prepared to go in support of his mission. His
commitment to his stakeholders, patients and stockholders alike, was revealed today
by the company's disclosure that Mr. Martin has been administered monthly doses
of Tysabri since February of this year, when the drug was unexpectedly pulled from
the market resulting from a PML scare.

CEO Martin commented: "We sat in the room. We poured over the results. We knew
it was safe. I'd even stake my own life on it. We knew there was a problem, but
in our heart of hearts it wasn't with Tysabri. We knew we'd have to have a safety
review, but I also wanted a way to make an irrefutable statement about what we felt
about the drug, so, I arranged to begin taking it myself. Everything I'd seen
convinced me it was completely safe."

Whilst Mr. Martin does not suffer from MS, CD or RA, he was at pains [sic] to point
out that his participation in this one-off "trial" was not to demonstrate efficacy,
but to show the world that the drug is absolutely safe.

When asked about side effects, Dr. Lars Ekman who has been personally monitoring
Mr. Martin said, "Kelly has suffered from absolutely no side effects whatsoever. In
fact, since we started him on Tysabri, we've noticed his performance in the board
room has improved considerably, with increased decisiveness and acuteness that is
unusually high even for the CEO of a large multinational biotech. What's more,
though he hasn't confirmed it personally, we are also led to believe that the boardroom
is not the only place his performance has improved." Watch out Pfizer. "Finally,"
said Dr. Ekman, "Kelly also remarked that he has had a reversal in his declining
hair coverage." Watchers at recent meetings and presentations had commented lately
that Mr. Martin was looking just a little more spritely over the last few months
than he had in February when the drug was pulled leading to the calamitous collapse of the share price.

Asked, where do you go from here, Mr. Martin responded; "Aside from my own personal
experiences with Tysabri, we still have a body of work to complete with the FDA
and European CHMP. However, we are working hard to expedite this and hope to bring
it to a close imminently. We're also currently in discussion with Jim Mullens to
see would he be willing to reciprocate by taking a six month course of Avonex in
combination with Steroids, however, so far he has not shown much enthusiasm for
this proposal."

-Paddystocks, in Dublin.

[kingofthehill]

http://finance.messages.yahoo.com/bbs?.mm=FN&action=m&board=7076797&tid=eln&sid=7076797&mid=754369

[Websman]

http://finance.messages.yahoo.com/bb...797&mid=754369

Looks like some changes are coming soon...

[skiracer]

With the situation with MRK it might be a bad atmosphere and time for any drug company to obtain the approval to bring a problem drug back onto the market. Especially here in the US.

[kingofthehill]

Merk Lied about Vioxx hid info, stalled over prescribed the drug, ran commericals for the drug ...Tysabri is a best in class drug for a very serious illness, dont get confused by Vioxx.

thats like saying because the Ford Pinto blew up on impact we are going to stop building cars.


anyway this is a speculative stock ..and i firmly believe the speculation is almost over and we will be back to market strong...hard to time options here if you get lucky you could really make a fortune..

[skiracer]

Wasn't trying to rain on anyone's parade. Just making a general comment on what the current mindset might be with the situation just happening with Merck. I hope you guys make a zillion on it but don't lose sight of the forest for the trees either.

[kingofthehill]

Thanks patience is a virtue

[Websman]

Thanks patience is a virtue

Truer words were never spoken.

Payday will be here soon enough.

[Websman]

Looks like our patience is starting to pay off King.